McKesson Forecasts $11.56 EPS and $101.9B Revenue Amid Negative Earnings ESP

Context McKesson (MCK) will release its first‑quarter 2026 results on May 7. The company, a leading distributor of prescription drugs, has been under close watch because its performance influences health‑care supply chains across the UK and beyond. Investors typically gauge stock movement by comparing actual results with consensus forecasts and the more recent Most Accurate Estimate, which reflects analysts’ latest information.

Key Facts - Projected earnings per share stand at $11.56, a 14.2% increase from the same quarter last year. - Revenue is forecast at $101.92 billion, up 12.2% year‑over‑year. - The Most Accurate Estimate falls below the consensus, generating an Earnings ESP of -0.07%. A negative ESP indicates recent analyst revisions have turned bearish, reducing confidence in a surprise beat. - McKesson holds a Zacks Rank of #3 (Hold), a neutral rating that further muddies the prediction of an earnings beat. - Historically, the company beat consensus EPS in each of the last four quarters, with the most recent quarter delivering a modest 0.32% surprise.

What It Means The earnings forecast signals solid top‑line growth, driven likely by higher drug volumes and expanded distribution services. However, the negative Earnings ESP reveals that analysts have recently trimmed expectations, perhaps reflecting concerns over pricing pressure, inventory adjustments, or macro‑economic headwinds.

Because the ESP model predicts beats reliably only when the signal is positive, the -0.07% reading offers no clear advantage. Combined with a neutral Zacks Rank, the odds of a surprise beat are ambiguous. Investors should watch the earnings call for commentary on margin trends, supply‑chain constraints, and any strategic initiatives that could offset the bearish tilt.

Looking Ahead The market will react sharply to whether McKesson can exceed the $11.56 EPS target and sustain the revenue surge. Pay close attention to management’s guidance for Q2 and any revisions to the earnings outlook, as these will shape the stock’s trajectory in the weeks following the report.